Cargando…
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
SIMPLE SUMMARY: The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evaluate the real-life pattern of use, efficacy, and sa...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122581/ https://www.ncbi.nlm.nih.gov/pubmed/33919277 http://dx.doi.org/10.3390/cancers13092002 |
_version_ | 1783692656771072000 |
---|---|
author | Wong, Jeffrey Sum-Lung Dong, Yawen Tang, Vikki Leung, Thomas Yeung, Cynthia S. Y. Tai, Anna Law, Ada Shum, Tracy Kwok, Gerry Gin-Wai Li, Bryan Cho-Wing Leung, Roland Chiu, Joanne Ma, Ka-Wing She, Wong-Hoi Tsang, Josephine Cheung, Tan-To Yau, Thomas |
author_facet | Wong, Jeffrey Sum-Lung Dong, Yawen Tang, Vikki Leung, Thomas Yeung, Cynthia S. Y. Tai, Anna Law, Ada Shum, Tracy Kwok, Gerry Gin-Wai Li, Bryan Cho-Wing Leung, Roland Chiu, Joanne Ma, Ka-Wing She, Wong-Hoi Tsang, Josephine Cheung, Tan-To Yau, Thomas |
author_sort | Wong, Jeffrey Sum-Lung |
collection | PubMed |
description | SIMPLE SUMMARY: The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evaluate the real-life pattern of use, efficacy, and safety of cabozantinib in aHCC patients in a territory-wide study. In single-agent cabozantinib patients (n = 27), we found that 3.7% had a response, 44.4% had disease control, and the median overall survival (OS) was 8.28 months. Around 74.1% of patients had adverse events (AEs). We also did an exploratory analysis of patients who received cabozantinib as an add-on to immune-checkpoint inhibitors (ICIs) after progression on ICIs. Out of 15 such patients, 6.7% had a response and the median OS was 15.1 months, with 73.3% of patients having AEs. Overall, cabozantinib had good efficacy, survival, and safety in aHCC patients in a real-life setting. ABSTRACT: (1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients. |
format | Online Article Text |
id | pubmed-8122581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81225812021-05-16 The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study Wong, Jeffrey Sum-Lung Dong, Yawen Tang, Vikki Leung, Thomas Yeung, Cynthia S. Y. Tai, Anna Law, Ada Shum, Tracy Kwok, Gerry Gin-Wai Li, Bryan Cho-Wing Leung, Roland Chiu, Joanne Ma, Ka-Wing She, Wong-Hoi Tsang, Josephine Cheung, Tan-To Yau, Thomas Cancers (Basel) Article SIMPLE SUMMARY: The vascular endothelial growth factor and c-MET pathways are strongly implicated in hepatocellular carcinoma (HCC). Cabozantinib inhibits both pathways and has been approved in sorafenib-exposed advanced HCC (aHCC). We aimed to evaluate the real-life pattern of use, efficacy, and safety of cabozantinib in aHCC patients in a territory-wide study. In single-agent cabozantinib patients (n = 27), we found that 3.7% had a response, 44.4% had disease control, and the median overall survival (OS) was 8.28 months. Around 74.1% of patients had adverse events (AEs). We also did an exploratory analysis of patients who received cabozantinib as an add-on to immune-checkpoint inhibitors (ICIs) after progression on ICIs. Out of 15 such patients, 6.7% had a response and the median OS was 15.1 months, with 73.3% of patients having AEs. Overall, cabozantinib had good efficacy, survival, and safety in aHCC patients in a real-life setting. ABSTRACT: (1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients. MDPI 2021-04-21 /pmc/articles/PMC8122581/ /pubmed/33919277 http://dx.doi.org/10.3390/cancers13092002 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wong, Jeffrey Sum-Lung Dong, Yawen Tang, Vikki Leung, Thomas Yeung, Cynthia S. Y. Tai, Anna Law, Ada Shum, Tracy Kwok, Gerry Gin-Wai Li, Bryan Cho-Wing Leung, Roland Chiu, Joanne Ma, Ka-Wing She, Wong-Hoi Tsang, Josephine Cheung, Tan-To Yau, Thomas The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study |
title | The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study |
title_full | The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study |
title_fullStr | The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study |
title_full_unstemmed | The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study |
title_short | The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study |
title_sort | use of cabozantinib in advanced hepatocellular carcinoma in hong kong—a territory-wide cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122581/ https://www.ncbi.nlm.nih.gov/pubmed/33919277 http://dx.doi.org/10.3390/cancers13092002 |
work_keys_str_mv | AT wongjeffreysumlung theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT dongyawen theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT tangvikki theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT leungthomas theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT yeungcynthiasy theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT taianna theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT lawada theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT shumtracy theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT kwokgerryginwai theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT libryanchowing theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT leungroland theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT chiujoanne theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT makawing theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT shewonghoi theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT tsangjosephine theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT cheungtanto theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT yauthomas theuseofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT wongjeffreysumlung useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT dongyawen useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT tangvikki useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT leungthomas useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT yeungcynthiasy useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT taianna useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT lawada useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT shumtracy useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT kwokgerryginwai useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT libryanchowing useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT leungroland useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT chiujoanne useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT makawing useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT shewonghoi useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT tsangjosephine useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT cheungtanto useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy AT yauthomas useofcabozantinibinadvancedhepatocellularcarcinomainhongkongaterritorywidecohortstudy |